Search results
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
Zacks via Yahoo Finance· 9 months agoQIAGEN N.V. QGEN recently announced the receipt of FDA approval for its therascreen PDGFRA RGQ PCR...
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Zacks via Yahoo Finance· 12 hours agoFor Immediate Release Chicago, IL – May 7, 2024 – Today, Zacks Equity Research discusses BioMarin...
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoBlueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal...
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
Zacks via Yahoo Finance· 2 years agoBlueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer...
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
Zacks via Yahoo Finance· 4 months agoBlueprint Medicines Corporation BPMC is focused on developing transformational precision medicines...
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
Zacks via Yahoo Finance· 4 months agoQIAGEN N.V. QGEN is likely to grow in the coming quarters, backed by its solid prospects in the...
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zacks via Yahoo Finance· 4 days agoBlueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust...
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
Zacks via Yahoo Finance· 3 months agoBlueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased...
Deciphera Pharmaceuticals (DCPH): An Intriguing Value Play with a Modestly Undervalued Market ...
GuruFocus.com via Yahoo Finance· 8 months agoDeciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a...
Deciphera Pharmaceuticals (DCPH): A Closer Look at Its Undervalued Status
GuruFocus.com via Yahoo Finance· 7 months agoDeciphera Pharmaceuticals Inc (NASDAQ:DCPH) recently reported a daily gain of 5.06%, despite a...